logo-loader

Oncimmune

Receive alerts
Market:
AIM
Market Cap:
£29.1 m
Price
46.00 GBX
Change
0.00%
52 weeks high
138.50
52 weeks low
45.00

In brief

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Deep dive We explore the investor case for growth companies

Snapshot

  • EarlyCDT test met primary endpoint in lung cancer study
  • Has European CE mark approval for the EarlyCDT- Lung test
  • Deal with Russia's leading drugmaker for EarlyCDT